AzTrials
AzTrials

Congenital Heart DiseasesFAST-CMRNCT07613398

An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

An observational study of Congenital Heart Diseases and Cardiac Diseases, run by Matthias Stuber at 20 sites in 10 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This project aims to evaluate a new cardiac MRI technique called the Free-Running Framework (FRF), which could simplify and accelerate the process of acquiring cardiac images. The investigators want to verify whether this method can provide functional heart measurements comparable to those obtained with traditional… Read more about this study

Who is it for?
Any age
Conditions the study is for
Congenital Heart Diseases, Cardiac Diseases
How many people
300 participants
Where
20 sitesin 10 countries
Study dates
Jun 2026to Sep 2030
How long will I take part?
1 Day
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: This study will prospectively include 300 patients (~15-20 per site) with known or suspected cardiac disease who are referred for a clinically indicated CMR scan as part of their routine clinical work-up.

Who may be able to join

  • Diagnosed with cardiac disease of any complexity and scheduled for a clinical cardiac MRI on a clinical 1.5T MRI scanner
  • Able to understand and provide written informed consent or, for minors, ability to provide assent with written consent from a parent/legal representative, per local law and site policy prior to the study
  • Ability to undergo MRI without contraindications
  • Agrees to be informed in the event of incidental findings

Who cannot join

  • Severe claustrophobia preventing MRI completion
  • Presence of non-MRI compatible implants (e.g., pacemakers, certain metallic implants)
  • Contraindications to the intravenous contrast agent
  • Movement disorders or inability to remain still during the scan

Trial locations and contacts

20 sites in 10 countries. Contact the study team or a site near you to ask about taking part.

Katerina Eyre, PhD contact

+41213147513

katerina.eyre@chuv.ch

Matthias Stuber, PhD contact

+41213147534

matthias.stuber@chuv.ch

20 sites in 10 countries

United States9 sites
  • Emory University

    Atlanta, Georgia, 30322

    John Oshinski, PhD, +1 404-727-5894, jnoshin@emory.edu

  • Boston's Children Hospital

    Boston, Massachusetts, 02115

    Andrew Powell, MD, +1 617-355-2079, andrew.powell@cardio.chboston.org

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611

    Joshua D. Robinson, MD, +1 312-227-4638, jdrobinson@luriechildrens.org

  • Ohio State University

    Columbus, Ohio, 43210

    Yuchi Han, MD, +1 614-292-6446, yuchi.han@osumc.edu

  • UT Southwestern Medical Center

    Dallas, Texas, 75390

    Franz Gerald Greil, MD, PhD, +1 214-648-3111, gerald.greil@utsouthwestern.edu

  • University of California, Los Angeles

    Los Angeles, California, 90095

    Kim-Lien Nguyen, MD, +1 (310) 825-1234, KimLienNguyen@mednet.ucla.edu

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

    Mark Fogel, MD, +1 215-590-3534, fogel@email.chop.edu

  • Mayo Clinic

    Rochester, Minnesota, 55902

    Tim Leiner, MD, PhD, +1 507-284-2511, leiner.tim@mayo.edu

  • Washington University in St. Louis

    St Louis, Missouri, 63130

    Pamela Woodard, MD, +1 314-747-3386, woodardp@nospam.wustl.edu

Other trials in United States

Germany3 sites
  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117

    Sebastian Kelle, MD, PhD, +493045931182, sebastian.kelle@dhzc-charite.de

  • University of Bonn

    Bonn, North Rhine-Westphalia, 53113

    Julian Luetkens, MD, PhD, +49 228 287 19860, Julian.Luetkens@ukbonn.de

  • Cologne University Medical Center

    Cologne, North Rhine-Westphalia, 50931

    David Maintz, MD, PhD, +49 221 478-82035, david.maintz@uk-koeln.de

Other trials in Germany

Australia1 site
  • University of Melbourne

    Melbourne, Victoria, 3010

    Ruth Lim, MD, +61 3 9035 5511, ruthplim74@gmail.com

Other trials in Australia

Colombia1 site
  • Fundacion Cardioinfantil-LaCardio

    Bogotá, Capital District, 111156

    Carlos Guerrero, MD, +57 (601) 744 2000, ceguerrero@lacardio.org

Other trials in Colombia

Italy1 site
  • Università Cattolica - Fondazione Policlinico Gemelli IRCCS

    Rome, Lazio, 00168

    Luigi Natale, MD, +971 56 666 0984, luigi.natale@unicatt.it

Other trials in Italy

Japan1 site
  • Mie University

    Tsu, Mie-ken, 514-8507

    Hajime Sakuma, MD, PhD, +81 59 231 5029, sakuma@med.mie-u.ac.jp

Other trials in Japan

Netherlands1 site
  • Maastricht University Medical Center

    Maastricht, Limburg, 6229 HX

    Robert J. Holtackers, PhD, +31 43 387 49 10, rob.holtackers@mumc.nl

Other trials in Netherlands

Singapore1 site
  • National University of Singapore

    Singapore, Singapore, 119275

    Liang Zhong, PhD, +65 67042237, gmszl@nus.edu.sg

Other trials in Singapore

South Africa1 site
  • University of Cape Town

    Cape Town, Western Cape, 7700

    Ntobeko Ntusi, MD, PhD, +27 21 406 6358, ntobeko.ntusi@uct.ac.za

Other trials in South Africa

United Kingdom1 site
  • King's College London

    London, London, WC2R2LS

    Amedeo Chiribiri, MD, PhD, +44 20 7188 8259, amedeo.chiribiri@kcl.ac.uk

Other trials in United Kingdom

About this study

Official title: Assessment and Validation of the Established Free-Running Framework for Cardiac Function by Magnetic Resonance Imaging (FAST-CMR): An International Multi-Center, Multi-Vendor Study at 1.5T

This project aims to evaluate a new cardiac MRI technique called the Free-Running Framework (FRF), which could simplify and accelerate the process of acquiring cardiac images. The investigators want to verify whether this method can provide functional heart measurements comparable to those obtained with traditional methods. More specifically, the goal of the study is to compare the measurements obtained with FRF to those obtained with standard sequences, to ensure they match and that this new approach can be reliably used in clinical practice. The FRF technique works differently from standard cardiac MRI. In standard exams, patients are asked to hold their breath several times and small electrodes (ECG) are used to monitor the heartbeat during the scan. These steps are needed to get clearer images of the heart as it moves. With FRF, these steps are no longer necessary: the scan is performed while patients' breath normally and without ECG monitoring. In addition, standard MRI takes multiple 2D slices of the heart, one after another. The FRF method instead captures a 3D image of the entire heart in one go, which can improve the consistency of the exam and reduce errors when doctors analyze the images later. This is all possible because the FRF method records data continuously and then organizes the images afterward based on how participants heart and breathing were moving during the exam. This helps the imager to get clear images of the heart, even without breath-holding or ECG monitoring. This project is aimed at individuals with heart disease who require cardiac MRI exams to monitor their health status (age ≥ 18 years) and are able to clearly understand the instructions provided by the research team. The investigators have already conducted small-scale technical and feasibility studies using FRF. These studies have shown that FRF is easy to use, faster than traditional methods, and provides image quality comparable to standard imaging techniques. The investigators now wish to evaluate its use in a clinical setting. More specifically, the investigators need to verify that FRF provides the same essential diagnostic information as standard techniques, so that it can be reliably used in future patient care. A maximum of 300 participants will be included in the investigation of this MRI technique between 2026 and 2031. This is a multi-center study, conducted internationally across 18 centers.

This project is being carried out in compliance with Swiss legislation. The investigators follow all internationally recognized guidelines. The competent ethics committee has reviewed and approved this project.

Read the detailed description

Cardiovascular disease remains the leading cause of death in industrialized nations. While a range of diagnostic tools exists for cardiovascular disease detection and monitoring, magnetic resonance imaging (MRI) remains the only modality that enables a safe, non-invasive assessment of the heart without exposure to ionizing radiation. MRI allows for a comprehensive evaluation of cardiac anatomy, function, myocardial tissue characterization, and blood flow quantification, making it a powerful tool for cardiovascular diagnostics.

Despite strong clinical evidence supporting its utility, cardiac MRI (CMR) remains underutilized, primarily due to the length and complexity of a traditional CMR exam. Several factors contribute to the length and complexity of a standard CMR exam. First, a standard CMR protocol relies heavily on two-dimensional (2D) image acquisitions, each requiring manual slice planning by an experienced technologist-a process that is both time consuming and highly dependent on operator expertise. Second, traditional image acquisition requires electrocardiogram (ECG) triggering to synchronize with the cardiac cycle, requiring additional setup and potentially introducing errors if the ECG signal is suboptimal. Finally, most conventional sequences rely on repeated patient breath-holding to minimize respiratory motion artifacts, which can be particularly challenging for individuals with severe cardiovascular disease, congenital anomalies, or limited compliance. Even for highly skilled personnel, this process is timeconsuming and inefficient. Consequently, a significant portion of the patient's time in the scanner is spent on preparation and planning rather than actual image acquisition, leading to prolonged exam durations and increased healthcare costs.

Given these challenges, there is a strong need for simplified, automated, and time-efficient CMR acquisitions. In response to this challenge, the investigators research group has developed an innovative "free-running framework" (FRF)-a set of MRI methods that continuously acquire threedimensional (3D) image data across the entire cardiac cycle and throughout free breathing, irrespective of cardiac or respiratory motion. Unlike conventional CMR sequences that require separate, prospectively planned acquisitions for each imaging plane and time point, FRF employs continuous, self-navigated data acquisition. This eliminates the need for complex slice planning and enables retrospective reconstruction of cardiac motion, ensuring that imaging is both standardized and independent of user expertise. By leveraging advanced motion-resolved reconstruction algorithms developed by the investigators group, the investigators can derive both cardiac and respiratory motion from a single dataset, providing a fully automated, 3D whole-heart imaging approach.

Once diagnosed, patients with cardiac diseases often require lifelong monitoring and repeated imaging assessments to guide treatment decisions and evaluate disease progression. This makes a non-ionizing imaging modality like CMR admirable. Nonetheless, the prolonged scan durations and intricate manual planning associated with traditional CMR limit its accessibility and practical feasibility. By eliminating the need for slice planning and reducing scan complexity, FRF has the potential to significantly improve imaging for cardiac disease patients by:

  • Standardizing imaging: producing user-independent results robust to anatomical variations.
  • Reducing scan times: without compromising diagnostic information.
  • Improving accessibility: enabling easier adoption in centers with less experienced technologists.

The feasibility of FRF has been demonstrated in experimental, pre-clinical, and small observational clinical studies, with no observed adverse effects. This study aims to evaluate its clinical feasibility and efficiency in real-world cardiac disease patients across multiple cardiac institutions, serving as a precursor for larger validation studies and eventual clinical implementation. This study will provide the first systematic clinical evaluation of 3D FRF across multiple cardiac institutions in cardiac disease patients, assessing both its technical feasibility and potential workflow benefits in a real-world setting. In particular, this study will:

  • Evaluate whether diagnostic information from FRF matches or exceeds standard CMR.
  • Assess the efficiency gains and the impact of automated, self-navigated imaging on scan duration and patient comfort.

If successful, this study will lay the groundwork for future multi-center validation clinical trial studies and eventual clinical integration, addressing a critical gap in CMR accessibility and efficiency.

Keywords
Free-running, Cine magnetic resonance imaging, Ventricular function, Multicenter, Multivendor, FISS (Fast- Interrupted Steady-State), Compressed sensing, Pragmatic clinical study
Medical subject headings
Heart Defects, Congenital, Heart Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07613398
Study groupRoleWhat they receive
Patients with congenital heart diseaseFAST-CMR will evaluate the technique's performance in complex, heterogeneous anatomy.
Patients unable to perform breath-holdingincluding those with advanced heart failure, pulmonary hypertension, or chronic obstructive pulmonary disease (COPD), representing a subgroup where conventional breath-held CMR techniques are often suboptimal or not feasible.
Other cardiovascular disease patients who are able to perform breath-holdingThis group represents the standard patient population for whom conventional CMR is currently optimized.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. mean paired difference (bias) in left ventricular ejection fraction (LVEF) between 5D FISS-FRF and conventional 2D cine CMR

    estimated with a two-sided 95% confidence interval within each pre-defined patient cohort. The study is designed to ensure that the half-width of this confidence interval does not exceed 1.25% LVEF per cohort.

    Measured: Baseline (during study MRI acquisition)

Secondary outcomes (20)
  1. Scan Efficiency

    • Sequence acquisition time: scanner-reported acquisition duration for 5D FISS-FRF and conventional 2D cine imaging. This will include the timing of the necessary localizers specific to the imaging plane for each acquisition mode.
    • Workflow time: elapsed time from initiation of cine planning to completion of cine acquisitions, including slice planning, patient instruction, rest between breath-holds, and repeated acquisitions when required.

    Measured: Baseline (during study MRI acquisition)

  2. Quantitative Image Quality

    • Contrast ratio and endocardial-to-blood-pool interface sharpness between 5D FISS-FRF and conventional 2D cine.

    Measured: Baseline (during study MRI acquisition)

  3. Qualitative Image Quality

    • Likert scale (0-4) consensus grading by ≥2 expert CMR readers blinded to images from both techniques.

    Measured: Baseline (during study MRI acquisition)

  4. Failure Rate

    • Percentage of non-diagnostic or excluded scans.

    Measured: Baseline (during study MRI acquisition)

  5. Anatomical Coverage

    • Extent of volumetric coverage of the entire heart and related great vessels.

    Measured: Baseline (during study MRI acquisition)

  6. Multiparametric Capability

    • Presence of additional diagnostic insights from respiratory motion tracking of FRF.

    Measured: Baseline (during study MRI acquisition)

  7. Clinical Acceptability of LVEF Measurements (±5% Threshold)

    • Exploratory analyses will assess whether observed agreement metrics are compatible with commonly used clinical acceptability thresholds (e.g., ±5% LVEF). These analyses are hypothesis-generating and intended to inform future confirmatory studies.

    Measured: Baseline (during study MRI acquisition)

  8. LV mass

    Comparison between 5D FISS-FRF and 2D conventional cine

    Measured: Baseline (during study MRI acquisition)

  9. Regional wall motion abnormalities

    assessed using a 4-point likert scale per AHA segment (normal, hypokinesia, akinesia, dyskinesia)

    Measured: Baseline (during study MRI acquisition)

  10. Left and right atrial volumes

    maximum and minimum volumes and total atrial emptying fraction derived from conventional 2D cine long-axis views compared to 5D FISS-FRF

    Measured: Baseline (during study MRI acquisition)

  11. Agreement of Automated Ventricular Ejection Fraction Measurements (LVEF, RVEF)

    Agreement of automatically post-processed ventricular ejection fraction measurements (LVEF, RVEF) derived from 5D FISS-FRF with (1) standard post-processing of 5D FISS-FRF and (2) standard post-processing of conventional 2D cine cardiac MRI. Agreement will be assessed using appropriate statistical metrics.

    Measured: Baseline (during study MRI acquisition)

  12. Agreement of Automated Ventricular Function Measurements (LVEDV, LVESV, LVSV, RVEDV, RVESV, RVSV)

    Agreement of automatically post-processed ventricular function metrics (LVEDV, LVESV, LVSV, RVEDV, RVESV, RVSV) derived from 5D FISS-FRF with (1) standard post-processing of 5D FISS-FRF and (2) standard post-processing of conventional 2D cine cardiac MRI. Agreement will be assessed using appropriate statistical metrics.

    Measured: Baseline (during study MRI acquisition)

  13. Feasibility of AI-Based Image Reconstruction

    Percentage of reconstructed datasets that are considered clinically usable based on predefined quality criteria.

    Measured: Baseline (during study MRI acquisition)

  14. Reconstruction Time

    Comparison of reconstruction time between AI-based reconstruction and standard compressed sensing methods.

    Measured: Baseline (during study MRI acquisition)

  15. Accuracy of Ventricular Ejection Fraction Measurements

    Comparison of left and right ventricular ejection fraction (LVEF, RVEF) between AI-based and standard reconstructions.

    Measured: Baseline (during study MRI acquisition)

  16. Accuracy of Ventricular Volume Measurements

    Comparison of left and right ventricular end-diastolic volume (EDV), end-systolic volume (ESV), and stroke volume (SV) between AI-based and standard reconstructions.

    Measured: Baseline (during study MRI acquisition)

  17. Accuracy of Left Ventricular Mass Measurements

    Comparison of left ventricular mass between AI-based and standard reconstructions.

    Measured: Baseline (during study MRI acquisition)

  18. Voxel-wise Image Similarity Between Reconstruction Methods

    Image similarity assessed using structural similarity index measure (SSIM), peak signal-to-noise ratio (PSNR), and root mean squared error (RMSE).

    Measured: Baseline (during study MRI acquisition)

  19. Quantitative Image Quality

    Contrast ratio and endocardial-to-blood-pool interface sharpness between reconstruction methods.

    Measured: Baseline (during study MRI acquisition)

  20. Qualitative Image Quality

    Likert scale (0-4) consensus grading by ≥2 expert CMR readers blinded to images from both reconstruction methods.

    Measured: Baseline (during study MRI acquisition)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2026
  2. Study startJun 2026 (estimated)
  3. Primary completionJan 2028 (estimated)
  4. Study completionSep 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
300 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07613398
Sponsor's protocol ID
2025-00923
Other IDs
2025
Acronym
FAST-CMR
Status last verified
Apr 2026
First submitted
27 Feb 2026
Last updated
29 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Ogier AC, Baup S, Ilanjian G, Touray A, Rocca A, Banus J, Monton Quesada I, Nicoletti M, Ledoux JB, Richiardi J, Holtackers RJ, Yerly J, Stuber M, Hullin R, Rotzinger D, van Heeswijk RB. Cardiac function assessment with deep-learning-based automatic segmentation of free-running four-dimensional whole-heart cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2026 Summer;28(1):102677. doi: 10.1016/j.jocmr.2025.102677. Epub 2025 Dec 24.

    PubMed 41453741
  • Koktzoglou I, Edelman RR. Radial fast interrupted steady-state (FISS) magnetic resonance imaging. Magn Reson Med. 2018 Apr;79(4):2077-2086. doi: 10.1002/mrm.26881. Epub 2017 Aug 30.

    PubMed 28856788
  • Yerly J, Roy CW, Milani B, Eyre K, Raifee MJ, Stuber M. High on sparsity: Interbin compensation of cardiac motion for improved assessment of left-ventricular function using 5D whole-heart MRI. Magn Reson Med. 2025 Mar;93(3):975-992. doi: 10.1002/mrm.30323. Epub 2024 Oct 9.

    PubMed 39385350
  • Bastiaansen JAM, Piccini D, Di Sopra L, Roy CW, Heerfordt J, Edelman RR, Koktzoglou I, Yerly J, Stuber M. Natively fat-suppressed 5D whole-heart MRI with a radial free-running fast-interrupted steady-state (FISS) sequence at 1.5T and 3T. Magn Reson Med. 2020 Jan;83(1):45-55. doi: 10.1002/mrm.27942. Epub 2019 Aug 27.

    PubMed 31452244
  • Di Sopra L, Piccini D, Coppo S, Stuber M, Yerly J. An automated approach to fully self-gated free-running cardiac and respiratory motion-resolved 5D whole-heart MRI. Magn Reson Med. 2019 Dec;82(6):2118-2132. doi: 10.1002/mrm.27898. Epub 2019 Jul 18.

    PubMed 31321816

Questions about this trial

What is this clinical trial studying?

An observational study of Congenital Heart Diseases and Cardiac Diseases, run by Matthias Stuber at 20 sites in 10 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in United States, Germany, Australia, Colombia, Italy and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Katerina Eyre, PhD (+41213147513, katerina.eyre@chuv.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

mean paired difference (bias) in left ventricular ejection fraction (LVEF) between 5D FISS-FRF and conventional 2D cine CMR (time frame: Baseline (during study MRI acquisition)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07613398, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in